Where does Centaurus Biopharma Co., Ltd. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Centaurus Biopharma Co., Ltd. ranks #9,227 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Centaurus Biopharma Co., Ltd. hold?

Centaurus Biopharma Co., Ltd. holds 34 US utility patents granted between 2016 and 2024, spanning 8 technology areas.

What is Centaurus Biopharma Co., Ltd.'s Innovation Score?

Centaurus Biopharma Co., Ltd. has an Innovation Score of 32.8 out of 100 (42nd percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Centaurus Biopharma Co., Ltd. focus on?

Centaurus Biopharma Co., Ltd.'s top technology area is C07D (Heterocyclic Compounds) with 32 patents, ranking #255 of 3,165 assignees active in that subclass. Grants appear in 8 CPC subclasses total.

Is Centaurus Biopharma Co., Ltd.'s patent grant rate increasing or decreasing?

Centaurus Biopharma Co., Ltd.'s recent grant velocity is +0% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Centaurus Biopharma Co., Ltd.'s patents?

Centaurus Biopharma Co., Ltd.'s patents average 15.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Centaurus Biopharma Co., Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Centaurus Biopharma Co., Ltd.

USPTO PatentsView assignee record - 34 granted patents across 8 technology areas, recorded in grant years 2016–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Centaurus ranks #9,227 of 49,997 tracked US assignees by granted-patent volume, with 34 patents across 8 technology areas.

#9,227
of 49,997 US assignees by volume: 42nd percentile
by Innovation Score (32.8/100): 15.8
avg claims per patent: +0%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R9227 · Foreign Corporation #9,227 · 34 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-FLAT · BOOK-FULL

GRANTS-SMALL 34 grants
UPPER-Q #9,227/49,997
PHOTO-FINISH Casco Signal
CPC-NARROW C07D · 8 areas
INNOV-THIN 32.8/100
CLAIMS-RICH 15.8 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-FLAT +0% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Casco Signal Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Centaurus’s 32.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 12.3 pts (37%) Velocity 1.1 pts (3%) Breadth 10.0 pts (30%) Claim depth 9.5 pts (29%)

Qualcomm Incorporated · highest

85
Centaurus Biopharma · this assignee

33
Fresh Idea Global · near

33
NeoMed · near

33
Life Fitness · near

33
Tosense · near

33
3D Lighting… · lowest

7

What this shows Centaurus's Innovation Score is 32.8/100 (42nd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Centaurus?

Each dot is one of Centaurus’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Centaurus’s own 15.8 claims/patent is ABOVE the 9.0 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Centaurus vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Centaurus's grants concentrate

Centaurus Biopharma Co., Ltd. is a focused PatentsView assignee: 8 CPC subclasses with 94.1% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2020 (10 grants) versus a trough of 1 in 2022. By volume, Centaurus sits between Casco Signal Ltd. and Clari Inc..

Centaurus's three-year grant acceleration

Centaurus Biopharma Co., Ltd. shows 3 grants in 2022–2024 against only 19 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Casco Signal

34
Cateye

34
CCS Technology

34
Ceat

34
Ceragem

34
Chongqing Institu…

34
Chungbuk National…

34
Clari

34
Centaurus Biophar… ◀

34

What this shows Centaurus holds 34 patents at rank #9,220, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Centaurus

By rank, the assignees closest to #9,220 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Centaurus's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Centaurus, neither rank-band nor same-CPC leaders (those blocks stay above). In C07D (Heterocyclic Compounds), Centaurus ranks #255 of 3,165 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (33 here).

Fresh Idea Global Limited 33 NeoMed, Inc. 33 Tosense, Inc. 33 Life Fitness, LLC 33

Centaurus's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

33 42nd percentile higher than 42% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Centaurus Biopharma Co., Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	2	5.9%
2017	4	11.8%
2018	6	17.6%
2019	5	14.7%
2020	10	29.4%
2021	4	11.8%
2022	1	2.9%
2023	1	2.9%
2024	1	2.9%

Which technologies does Centaurus Biopharma Co., Ltd. patent most?

C07D - Heterocyclic Compounds 32

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 31

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 21

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 9

C07C - Acyclic OR Carbocyclic Compounds 6

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 2

B01D - Separation 1

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 1

Top 8 of 8 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Centaurus Biopharma Co., Ltd.'s patent record in context - here's where to go next.

Centaurus Biopharma Co., Ltd.'s lead technology class is C07D (Heterocyclic Compounds), 94.1% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #9,227 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Centaurus Biopharma Co., Ltd. against Casco Signal Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 32.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.